Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Decreases By 96.7%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 24 shares, a drop of 96.7% from the January 29th total of 725 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,057 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 2,057 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the 3rd quarter valued at $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $204,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Tema Etfs LLC acquired a new stake in Ascentage Pharma Group International in the second quarter worth about $610,000.

Analysts Set New Price Targets

Several research firms have issued reports on AAPG. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $48.40.

Ascentage Pharma Group International Stock Performance

AAPG opened at $24.10 on Friday. Ascentage Pharma Group International has a 1-year low of $17.56 and a 1-year high of $48.45. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The firm has a 50-day moving average price of $25.85 and a two-hundred day moving average price of $32.78.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.